Research dosage protocols vary depending on study objectives, laboratory requirements, and experimental design
Dysregulation of the UPS and interferon-beta (IFN-) signaling contributes to MS development, making UPS components potential therapeutic targets
Injection mixtures containing Pser-7::ser-7::SL2::GFP (30 ng/uL), Pflp-21::ser-7::SL2::GFP (30 ng/uL), Pdel-7::ser-7::SL2::GFP (30 ng/uL), Pceh-28::ser-7::SL2::GFP (30 ng/uL), Pceh-19::ser-7::SL2::GFP (30 ng/uL), Pceh-53::ser-7::SL2::GFP (30 ng/uL), Pceh-45::ser-7::SL2::GFP (30 ng/uL), Plgc-8::ser-7::SL2::GFP (30 ng/uL), or Pflp-15::ser-7::SL2::GFP (30 ng/uL) together with the co-injection marker Pmyo-3::mCherry (3 ng/uL) were injected into DA2100 ser-7(tm1325) X
These reports are intriguing and deserve further scientific exploration to understand potential mechanisms, such as the modification of gut microbiota or inflammation pathways